A study evaluating clinical outcomes of patients treated with osimertinib in patients previously treated with EGF816 for assessing cross resistance between EGF816 and osimertinib.
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Osimertinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology